Brainomix Secures £14M to Revolutionize Stroke and Lung Fibrosis Treatment
March 21, 2025, 9:33 am
In the fast-paced world of healthcare technology, Brainomix is making waves. The Oxford-based company has just raised £14 million in Series C funding. This investment is a lifeline, aimed at expanding its reach into the U.S. market. With a focus on AI-powered imaging tools, Brainomix is poised to change the landscape of stroke and lung fibrosis treatment.
The funding round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund (BIVF), with new backing from Hostplus via the IP Group Hostplus Innovation Fund. This diverse group of investors sees the potential in Brainomix’s innovative approach. They recognize that the company is not just another tech startup; it’s a beacon of hope for patients suffering from debilitating conditions.
Brainomix’s journey began as a spinout from the University of Oxford. Since its inception, it has grown rapidly, now operating in over 20 countries. The company specializes in AI-driven software solutions that enhance treatment decisions for stroke and lung fibrosis patients. Its flagship product, Brainomix 360 Stroke, automates imaging biomarkers, streamlining the diagnostic process. This technology has already been deployed in more than 300 hospitals, benefiting over 1.5 million patients.
The impact of Brainomix’s technology is profound. Studies show that its platform has led to a 50% increase in the number of patients receiving mechanical thrombectomy, a critical treatment that can significantly reduce disability after a stroke. This statistic is not just a number; it represents lives changed and futures secured.
The recent funding will allow Brainomix to accelerate its commercial expansion into the U.S. market. The company has already secured ten FDA clearances, a significant milestone that opens doors to new opportunities. With this funding, Brainomix aims to enhance its portfolio of AI-powered technologies, facilitating faster diagnoses and increasing access to life-saving treatments.
The leadership at Brainomix is confident. Dr. Michalis Papadakis, the CEO, emphasizes the transformative potential of their technology. He believes that with the right support, Brainomix can achieve broad success in the U.S., ultimately improving patient care and access to essential therapies. The company’s partnership with Boehringer Ingelheim, a leader in lung fibrosis treatments, further solidifies its position in the market. Together, they are evaluating the real-world impact of Brainomix’s e-Lung technology, which predicts disease progression and enhances treatment identification.
The support from investors is a testament to the company’s vision. Parkwalk Advisors, a prominent player in the HealthTech investment space, sees the societal impact of Brainomix’s solutions. They recognize that the potential for AI in healthcare is not just theoretical; it’s already making a difference. The investment will not only fuel Brainomix’s growth but also create jobs and support more patients in need.
As Brainomix expands, it plans to grow its team. Currently, the company employs over 75 staff members, and it aims to bolster its Oxford-based operations and global commercial team. This growth is essential for maintaining momentum and ensuring that the company can meet the increasing demand for its innovative solutions.
The landscape of healthcare is evolving. AI is no longer a futuristic concept; it’s a reality that is reshaping how we approach diagnosis and treatment. Brainomix stands at the forefront of this revolution. Its commitment to harnessing AI for better patient outcomes is commendable. The company’s technology is not just about efficiency; it’s about saving lives.
In a world where time is of the essence, Brainomix’s tools provide a crucial advantage. Quick and accurate diagnoses can mean the difference between life and death. As the company continues to innovate, it will undoubtedly play a pivotal role in the future of healthcare.
The funding secured by Brainomix is more than just capital; it’s a vote of confidence in the power of technology to transform lives. With the backing of seasoned investors and a clear vision for the future, Brainomix is set to make significant strides in the U.S. market. The journey ahead is promising, and the potential for impact is immense.
In conclusion, Brainomix is not just another tech company; it’s a lifeline for patients battling stroke and lung fibrosis. With its recent funding, the company is ready to take on new challenges and expand its reach. The future looks bright for Brainomix, and with it, the promise of better healthcare for all. As they say, the best is yet to come.
The funding round was co-led by Parkwalk Advisors and the Boehringer Ingelheim Venture Fund (BIVF), with new backing from Hostplus via the IP Group Hostplus Innovation Fund. This diverse group of investors sees the potential in Brainomix’s innovative approach. They recognize that the company is not just another tech startup; it’s a beacon of hope for patients suffering from debilitating conditions.
Brainomix’s journey began as a spinout from the University of Oxford. Since its inception, it has grown rapidly, now operating in over 20 countries. The company specializes in AI-driven software solutions that enhance treatment decisions for stroke and lung fibrosis patients. Its flagship product, Brainomix 360 Stroke, automates imaging biomarkers, streamlining the diagnostic process. This technology has already been deployed in more than 300 hospitals, benefiting over 1.5 million patients.
The impact of Brainomix’s technology is profound. Studies show that its platform has led to a 50% increase in the number of patients receiving mechanical thrombectomy, a critical treatment that can significantly reduce disability after a stroke. This statistic is not just a number; it represents lives changed and futures secured.
The recent funding will allow Brainomix to accelerate its commercial expansion into the U.S. market. The company has already secured ten FDA clearances, a significant milestone that opens doors to new opportunities. With this funding, Brainomix aims to enhance its portfolio of AI-powered technologies, facilitating faster diagnoses and increasing access to life-saving treatments.
The leadership at Brainomix is confident. Dr. Michalis Papadakis, the CEO, emphasizes the transformative potential of their technology. He believes that with the right support, Brainomix can achieve broad success in the U.S., ultimately improving patient care and access to essential therapies. The company’s partnership with Boehringer Ingelheim, a leader in lung fibrosis treatments, further solidifies its position in the market. Together, they are evaluating the real-world impact of Brainomix’s e-Lung technology, which predicts disease progression and enhances treatment identification.
The support from investors is a testament to the company’s vision. Parkwalk Advisors, a prominent player in the HealthTech investment space, sees the societal impact of Brainomix’s solutions. They recognize that the potential for AI in healthcare is not just theoretical; it’s already making a difference. The investment will not only fuel Brainomix’s growth but also create jobs and support more patients in need.
As Brainomix expands, it plans to grow its team. Currently, the company employs over 75 staff members, and it aims to bolster its Oxford-based operations and global commercial team. This growth is essential for maintaining momentum and ensuring that the company can meet the increasing demand for its innovative solutions.
The landscape of healthcare is evolving. AI is no longer a futuristic concept; it’s a reality that is reshaping how we approach diagnosis and treatment. Brainomix stands at the forefront of this revolution. Its commitment to harnessing AI for better patient outcomes is commendable. The company’s technology is not just about efficiency; it’s about saving lives.
In a world where time is of the essence, Brainomix’s tools provide a crucial advantage. Quick and accurate diagnoses can mean the difference between life and death. As the company continues to innovate, it will undoubtedly play a pivotal role in the future of healthcare.
The funding secured by Brainomix is more than just capital; it’s a vote of confidence in the power of technology to transform lives. With the backing of seasoned investors and a clear vision for the future, Brainomix is set to make significant strides in the U.S. market. The journey ahead is promising, and the potential for impact is immense.
In conclusion, Brainomix is not just another tech company; it’s a lifeline for patients battling stroke and lung fibrosis. With its recent funding, the company is ready to take on new challenges and expand its reach. The future looks bright for Brainomix, and with it, the promise of better healthcare for all. As they say, the best is yet to come.